All posts by imreal

Cardiac Imaging, ECG and the Role for Patient-Reported Outcomes, Upcoming Webinar Hosted by Xtalks


Cardio-oncology, an evolving subspecialty focused specifically on the detection and management of these risks, has become an essential consideration within any oncology development program.

As clinical research in the oncology therapeutic area becomes increasingly complex, effectively capturing high-quality data across multiple endpoints becomes even more critical to a drug’s success. Many oncologic agents have cardiac toxicities, including depression of left ventricular function, QTc prolongation and elevation of blood pressure.

Register for this webinar to learn about the intersection of oncology drug development and cardiac safety, and how this new area is changing the landscape for early-phase clinical trials.

Cardio-oncology, an evolving subspecialty focused specifically on the detection and management of these risks, has become an essential consideration within any oncology development program. Additionally, with the growing emphasis on patient-focused drug development, recent regulatory guidelines now outline core patient-reported outcomes (PROs) that should be included in oncology clinical trials.

Among these are self-reported symptomatic adverse events, with the new 2023 US Food and Drug Administration (FDA) draft guidance acknowledging the importance of utilizing this self-reported data to enhance the assessment of tolerability in early-phase dose optimization trials.

To accommodate the recommendations for enhanced detection strategies, the featured speakers will discuss key topics, including: Feasibility and best practices for PRO collection; Technologies for ECG collection; Blood pressure monitoring and cardiac imaging; And enhancing data quality without substantially increasing patient burden.

The integration of objectively measured safety endpoints with PROs is essential in characterizing the safety profile of a drug, which ultimately informs the overall benefit-risk considerations for the program.

Join this webinar for an introduction to cardio-oncology and ECG best practices, as well as a discussion of the benefits of PROs.

Join experts from Clario, Todd Rudo, MD, EVP & Chief Medical Officer; Robert Kleiman, MD, Vice President & Chief Medical Officer, Cardiology; Mori Krantz, MD, Senior Cardiologist, Chief Science Advisor, Cardiac Safety & Cardiovascular Imaging; and Kelly Dumais, PhD, Principal Scientific Advisor, for the live webinar on Tuesday, April 11, 2023, at 11am EDT (4pm BST/UK).

For more information, or to register for this event, visit Safety and Tolerability in Oncology Trials: Cardiac Imaging, ECG and the Role for Patient-Reported Outcomes.

ABOUT XTALKS

Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars to the global life science, food and medical device community. Every year, thousands of industry practitioners (from life science, food and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access to quality content. Xtalks helps Life Science professionals stay current with industry developments, trends and regulations. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.

To learn more about Xtalks visit http://xtalks.com

For information about hosting a webinar visit http://xtalks.com/why-host-a-webinar/

Contact:

Vera Kovacevic

Tel: +1 (416) 977-6555 x371

Email: vkovacevic@xtalks.com

Share article on social media or email:

New KnowBe4 SecurityCoach Integrates With Cloudflare’s Cloud Email Security


SecurityCoach helps IT/security professionals to develop a strong security culture by enabling real-time security coaching of their users in response to risky security behavior.

KnowBe4, the provider of the world’s largest security awareness training and simulated phishing platform, today announced that its new SecurityCoach product integrates with Cloudflare’s cloud email security. The two security organizations have collaborated together to help reduce risky behavior with product integration to support real-time security coaching.

SecurityCoach helps IT/security professionals to develop a strong security culture by enabling real-time security coaching of their users in response to risky security behavior. Leveraging an organization’s existing security stack, IT/security professionals can configure their real-time coaching campaigns to immediately deliver a SecurityTip to their users related to a detected event.

“Cloudflare joins our ecosystem of technology partners, which is growing rapidly, to enrich the support we provide to our customers and to fortify their organization’s human firewall,” said Stu Sjouwerman, CEO, KnowBe4. “KnowBe4 is proud to work with Cloudflare to provide a seamless integration with our new SecurityCoach product, which aims to deliver real-time security coaching and advice to help end users enhance their cybersecurity knowledge and strengthen their role in contributing to a strong security culture. KnowBe4 is actively working with Cloudflare to provide an API-based integration to connect our platform with systems that IT/security professionals already utilize, making rolling out new products to their teams an easy and unified process.”

“When we’re talking to CISOs—whether at Fortune 500s, startups, or non-profits — email security emerges as the biggest threat vector that they face,” said Alex Dyner, Senior Vice President, Special Projects at Cloudflare. “We are excited to integrate with KnowBe4 to allow our mutual customers to offer real-time coaching to their employees when a phishing campaign is detected by Cloudflare’s cloud email security. This will help in reducing the human errors that lead to phishing attacks.”

KnowBe4 will provide step-by-step instructions and recommendations to help IT/security professionals achieve quick and pain-free integration and data syncing during the implementation process.

KnowBe4 now integrates or partners with over 20 of the world’s top cybersecurity platforms across Endpoint, Network, Identity, Cloud and Data Security https://www.knowbe4.com/integrations. For more information on SecurityCoach, visit https://www.knowbe4.com/products/securitycoach.

To learn more about the integration, read this blog from Cloudflare https://blog.cloudflare.com/Knowbe4-emailsecurity-integration

About KnowBe4

KnowBe4, the provider of the world’s largest security awareness training and simulated phishing platform, is used by more than 56,000 organizations around the globe. Founded by IT and data security specialist Stu Sjouwerman, KnowBe4 helps organizations address the human element of security by raising awareness about ransomware, CEO fraud and other social engineering tactics through a new-school approach to awareness training on security. Kevin Mitnick, an internationally recognized cybersecurity specialist and KnowBe4’s Chief Hacking Officer, helped design the KnowBe4 training based on his well-documented social engineering tactics. Tens of thousands of organizations rely on KnowBe4 to mobilize their end users as their last line of defense.

Cloudflare, the Cloudflare logo, and other Cloudflare marks are trademarks and/or registered trademarks of Cloudflare, Inc. in the U.S. and other jurisdictions.

Share article on social media or email:

Whitney Scholarship Fund will Benefit Brunswick High School Graduates


Nancy H. Whitney

The Nancy H. Whitney, R.N. Scholarship Fund has been established with The Community Foundation of Frederick County and becomes one of its more than 770 component charitable funds.

To honor their mother and her positive impact on those around her, Jana Lamonica, Amy Whitney, and Stephen Whitney have created The Nancy H. Whitney, R.N. Scholarship Fund. Nancy worked as a registered nurse at Frederick Health Hospital and was committed to whole-person health care. Her husband, Joseph, had a final wish that this fund be created in his wife’s memory so her legacy of care and dedication within the community would continue. The fund will provide financial assistance for Brunswick High School graduates, including nontraditional students, pursuing an education in the healthcare field.

As a leader in grant and scholarship funding, The Community Foundation of Frederick County has given back more than $86 million to the community since 1986.

To learn more about how the Community Foundation impacts Frederick County, visit http://www.FrederickCountyGives.org.

Share article on social media or email:

There’s No Escaping the New Hypervisual World; Men Take a Page From the Women’s Virtual Playbook


News Image

The stigma of vanity surrounding cosmetic procedures for men has evaporated. Minimally invasive treatments with little downtime and natural-looking results give men the same benefits women have enjoyed for decades — enhanced self-esteem, confidence, and sociability

Men’s approach to skincare has been historically minimalistic — soap, water, shave, repeat. Their number one grooming accessory, the razor, has evolved over the decades from one single blade to up to five and counting. Until recently, men seemingly stuck to the conventional notion that men, as opposed to women, “look better as they age.” Or, so the story goes — or went. However, civilization has become high-tech and hypervisual, and there are metaphorical mirrors everywhere — selfies, social media, videoconferencing — and it’s not always possible to hide behind an anti-aging filter. Once considered a “metrosexual” indulgence, men increasingly view aesthetic enhancements as a necessary investment to boost self-confidence and succeed in a virtual business world. Cynthia Elliott, MD, owner and primary practitioner of Skinspirations, says, “The stigma of vanity surrounding cosmetic procedures for men has evaporated. Minimally invasive treatments with little downtime and natural-looking results give men the same benefits women have enjoyed for decades — enhanced self-esteem, confidence, and sociability.”

According to a study by The American Society of Plastic Surgeons, between 2000 and 2020, for men, there has been a 137% increase in soft tissue fillers, a 182% increase in skin rejuvenating injectables, and a 482% increase in laser skin resurfacing. (1) While it’s been generally accepted that female celebrities maintain their flawless skin and youthful appearance with routine aesthetic treatments, it’s taken a bit longer for famous men to come out of the shadows regarding what the zeitgeist endearingly refers to as “Brotox.” Men are turning to aesthetic treatments to maximize their potential in all aspects of their lives.

The International Society of Aesthetic Plastic Surgery reported that male cosmetic procedures have increased by more than 325% since 1997. And one not-so-surprising motivator, aside from having a dynamic social media presence, is the proliferation of Marvel movies, with men who ooze masculinity and are the archetypal embodiment of male perfection. (2) At Skinspirations, increasingly popular male aesthetic treatments include sculpting strong and chiseled jawlines, higher cheekbones, body contouring, unwanted hair, vein & spot removal, tattoo removal or fading, hair growth, and acne scar treatments.

There is still a vestige of bias when it comes to men taking advantage of the same non-invasive and revolutionary aesthetic treatments now widely available to the general public, not just the privileged elites. For male and female celebrities, cosmetic procedure failures tend to get more attention than successes. However, male celebrity procedural misses tend to get a louder thumping on social media than their female counterparts.

Dr. Elliott emphasizes that “Experience and integrity matter. Skinspirations is a medical practice, not a spa. Our team of licensed providers is exceedingly knowledgeable and highly skilled in using the tools and medical-grade products not offered through med spas. All of us at Skinspirations have a passion for providing our patients with the most honest and knowledgeable advice possible to address their aesthetic concerns, even if it means telling them they don’t need any of our services.”

Contrary to the now-defunct Marlboro Man image of rugged masculinity, today’s men are breaking free from a singular perception of maleness toward a broader range of thinking, where men can be more open about their insecurities and take more confident steps toward improving their exterior and interior self in an increasingly meta worldview.

About Dr. Cynthia Elliott and Skinspirations

Cynthia Elliott, M.D., is the owner and primary practitioner of Skinspirations, a cosmetic and regenerative medical practice that provides injectable and laser aesthetic treatments, professional skincare, body contouring, and regenerative treatments for aesthetic and musculoskeletal concerns. Located in Clearwater, Florida, Dr. Elliott is valued for her medical expertise and her training on the national level for the makers of Botox® Cosmetic and Juvéderm and internationally for Cutera Lasers. Her patients seek her expertise, knowing that she and her long-tenured staff have trained many professionals in the Tampa Bay area. Skinspirations has performed over 88,000 cosmetic medical treatments since 2005 and is known for the most effective aesthetic and regenerative medical treatments available, providing the quality results that other practitioners are still trying to learn. Dr. Elliott, whose medical training began in emergency medicine, currently serves as an expert witness in Cosmetic Medicine for the Florida Board of Medicine.

For more information, visit http://www.skinspirations.com.

Sources:

1. Cosmetic surgery gender distribution male – American society of plastic … (n.d.). Retrieved February 21, 2023, from plasticsurgery.org/documents/News/Statistics/2020/cosmetic-procedures-men-2020.pdf

2. “Do All Men Want to Look like Superheroes, the Zoom Focus on Facial Flaws, Nose Tip Droopage, Treatments for Profuse Sweating.” Skinspirations, myemail.constantcontact.com/Do-all-men-want-to-look-like-superheroes–the-Zoom-focus-on-facial-flaws–nose-tip-droopage—-treatments-for-profuse-sweating.html?soid=1101853765215;aid=z24Ucoqna8Q.

Share article on social media or email:

ScitoVation Announces Next Generation, Non-animal Genotoxicity Program


ScitoVation - Pioneers in chemical safety assessments

Pioneers in chemical safety assessments

Our genotox program is aimed at identifying potential genotoxicity hazards early, saving time and resources by reducing the potential for positive outcomes in the regulatory genetic toxicology test battery that can stop further development

ScitoVation today announced the availability of next generation, non-animal genotoxicity assays for lead candidate selection. These assessments will provide clients genotoxicity assessments during drug discovery or early lead compound development that are highly predictive of outcomes from the regulatory genetic toxicology test battery.

Knowledge regarding the potential of pharmaceuticals, food additives or chemicals to damage the human genome and cause mutations remains critical to public health. Mutations are key events in the induction of cancer, birth defects, and neurological disease. The regulatory genetic toxicology test battery required by the US Food and Drug Administration (FDA) for Investigational New Drug applications to initiate clinical trials, and by the US Environmental Agency (EPA) for registration of pesticides, includes approved in vitro tests for assessing genotoxicity and mutagenicity. A positive response in this regulatory test battery can eliminate drug candidates from further development or require further in vivo testing to demonstrate safety, which add significant time to development and can be costly.

ScitoVation’s New Genotoxicity Program includes:

  • Computational Tools for Testing Mutagenicity (AMES Test): Quantitative structural-activity relationship (QSAR) tools that are highly predictive of bacterial mutagenicity test (Ames Test). The use of QSAR offers an efficient means from both cost and timing perspective to triage candidates and focus additional in vitro testing on more promising candidates.
  • Micronucleus Assay: For lead candidates, the OECD approved in vitro micronucleus assay using human TK6 or HepaRG™ cells.
  • Toxicogenomic Genotoxicity Biomarker TgX-DDI: provides a point of departure that can be used to translate the in vitro results to human equivalent dose. This biomarker is currently undergoing FDA validation as biomarker predictive of mammalian genotoxicity.

Current genetic toxicology assessments are increasingly challenging due to backlogs and outdated technologies. ScitoVation’s Chief Scientific Officer and program creator, Leslie Recio, PhD, explains, “Our genotox program is aimed at identifying potential genotoxicity hazards early, saving time and resources by reducing the potential for positive outcomes in the regulatory genetic toxicology test battery that can stop further development.”

Dr. Jean Orelien, ScitoVation CEO, is pleased to offer this program to clients: “I’m pleased that in addition to providing the regulatory accepted micronucleus assay, consistent with our commitment to innovate for our clients, we will provide additional value by helping our clients assess genotoxicity using promising novel methods such as toxicogenomics.”

ScitoVation is focused on modernizing safety assessment for early-stage development using human biological models integrated with mode-of-action genomic and computational toxicology tools as New Approach Methodologies (NAMs) for human risk assessments.

Ordering for the micronucleus assay will open on April 2nd. Please visit http://www.scitovation.com/genotoxicity for more information.

About ScitoVation

ScitoVation helps clients develop safer and more effective pharmaceuticals, food ingredients, agricultural chemicals, commodity chemicals, and consumer products using innovative science and next generation technology.  The company is known for partnership, flexibility, and proven success in assisting clients to address safety and effectiveness for both internal stakeholders and regulators. Recognized as industry experts in the use of New Approach Methods (NAMs), the team pioneered cell-based and computational methods to provide leading-edge solutions with results that are scientifically sound and withstand scrutiny, including from peer-reviewers and regulators.

Share article on social media or email:

Riverside Insights and Kognito Partner to Offer Intervention Professional Development for School Health Providers


Riverside Insights

The reality is that 75% of mental health conditions emerge by the age of 14, but often the evidence is misattributed as the child being apathetic or disengaged.

Riverside Insights®, a leading developer of research-based assessments and analytics, today announced a partnership with Kognito, a provider of practice-based digital learning experiences, which provides strategies to improve mental health and well-being across schools. With this collaboration, school health professionals, such as psychologists, counselors and school nurses, will have access to additional training to support mental health-related cognitive interventions for at-risk students.

Centers for Disease Control and Prevention (CDC) research shows that in 2021 more than four in 10 students felt persistently sad or hopeless and nearly one-third (29%) experienced poor mental health. Through the partnership, health professionals will have additional training to notice the early signs and establish a therapeutic collaboration with the student.

“Riverside Insights’ partnership with Kognito is another example of our commitment to supporting the whole child,” said Sunjay Talele, clinical general manager at Riverside Insights. “School health professionals play a critical role in identifying and supporting students with behavioral or mental health concerns. Together we can provide the tools and training necessary to effectively manage the specific conversation with each student to motivate healthy behaviors.”

Now, school health professionals and educators will have access to a variety of interactive trainings that are proven to lead to more impactful conversations and outcomes with students. The Kognito Learning Model includes the following key components:


  • Didactic Lessons + Interactive Conversations: Learners gain key knowledge in conversation and social and emotional learning (SEL) skills, followed by practice opportunities. This practice-based experiential learning builds the skills and confidence needed to effectively approach important conversations.
  • Real-Life Scenarios: Relatable scenarios evoke an emotional response to create a powerful experience. Content is based on the input of thousands of educators and students and reveals the cause and effect relationship between the learners’ communication strategies and the responses they elicit.
  • Virtual Coaches: Learners have access to virtual coaching in the platform, which allows for more transformative learning moments where the user can reflect on how they are doing and what steps they can take to improve. This allows for a deeper understanding of the communication strategies taught.
  • Kognito Virtual Humans: Each Kognito simulation consists of interactive didactic modules and a series of roleplay conversations. Users engage in hands-on practice leading conversations with virtual, fully animated and emotionally responsive humans. Kognito’s virtual humans are scientifically designed to embody specific personalities, attitudes, and medical/behavioral health conditions.

“The reality is that 75% of mental health conditions emerge by the age of 14, but often the evidence is misattributed as the child being apathetic or disengaged,” said Deborah Serri, vice president of Product, Kognito. “The Kognito training helps guide school health professionals, nurses, psychologists, teachers, and counselors so they can identify warning signs early. Kognito role-play simulations enable schools and districts to rapidly build the capacity of educators and students to lead real-life conversations that change lives.”

About Kognito

Kognito is a leading provider of practice-based digital learning experiences that provide strategies to improve mental health and well-being across schools, campuses, and communities. Built on an interactive platform, the products integrate several evidence-based models and techniques, game mechanics, and learning principles, allowing users to learn by engaging in role-play conversations with emotionally responsive humans. Through practice and personalized feedback, users learn and assess their competency to lead similar real-life conversations. Kognito has been instrumental in providing training to over 1.5 million educators, administrators, students, and their communities. This innovative approach is changing lives by increasing user confidence and awareness on critical topics that impact critical thinking and decision-making. For more information, visit kognito.com.

About Riverside Insights

Riverside Insights, one of the nation’s leading and most long-standing developers of research-based assessments, is led by a powerful mission: to provide insights that help elevate potential and enrich the lives of students, clinical patients, employees, and organizations globally. For more information, visit http://www.RiversideInsights.com.

Share article on social media or email:

Proscia Announces Major Expansion In Preclinical R&D To Drive Faster Drug Safety Decisions


“Expanding our solutions for preclinical R&D came in response to customer demand. We are helping them to increasingly realize the efficiency and quality gains that Concentriq for Research delivers as the place where work happens and data lives.” – Nathan Buchbinder, Proscia’s Chief Product Officer

Proscia®, a leading provider of digital and computational pathology solutions, has strengthened its position in the $12 billion[1] preclinical research and development (R&D) market. At the center of its expansion, the company is enhancing its flagship Concentriq® for Research, trusted by 14 of the top 20 pharmaceutical companies as a singular software platform for pathology workflows and data, to accelerate Good Laboratory Practice (GLP) and non-regulated drug safety studies.

Preclinical R&D, which demonstrates if a drug is safe to advance to human clinical trials, centers around workflows with higher volumes of pathology data than any other phase of drug discovery and development. Life sciences organizations are now rapidly adopting digital pathology to drive efficiency and quality gains in their routine operations, streamlining collaboration and improving the reproducibility of results.

“Digital pathology is enabling preclinical pathology and R&D teams to do their jobs better,” said Aleksandra Zuraw, Veterinary Pathologist, Digital Pathologist, and Publisher of Digital Pathology Place. “By shifting from microscope to whole slide image, scientists can work more productively and deliver more consistent results.”

Announced today, Proscia is extending the scalable, intuitive Concentriq for Research to increasingly drive preclinical R&D with new features and services including:

  • Robust capabilities for GLP compliance. Life sciences organizations can conduct GLP studies in the same platform as their non-regulated discovery and preclinical research. In addition to offering audit logs, enterprise administration, and archiving workflows on Concentriq for Research, Proscia has made available GLP validation services to help teams realize the benefits of digital pathology sooner.
  • A new Studies module that streamlines toxicopathology workflows. Concentriq for Research now enables whole slide image scoring and peer review with the introduction of a Studies module. Scientists can manage study frameworks, simultaneously collect pathologists’ assessments, and instantly evaluate results, easily capturing structured data to help improve reproducibility and drive more efficient analysis.
  • Expanded Automated Quality Control (QC) for preclinical image data. On top of improving the performance of the platform’s embedded Automated QC on images of H&E stained slides, Proscia has expanded it to also detect commonly occurring quality issues on images of immunohistochemistry (IHC) and special stained slides. Regions of interest can be shared with integrated image analysis applications to further ensure the quality of study data.

“Expanding our solutions for preclinical R&D was an obvious step for us that came in response to growing customer demand,” said Nathan Buchbinder, Proscia’s Chief Product Officer. “These life sciences organizations are making important drug safety decisions that play a key role in getting new therapies to patients. We are now helping them to increasingly realize the efficiency and quality gains that Concentriq for Research delivers as the place where work happens and data lives.”

A modern pathology platform, Concentriq for Research is used by leading pharmaceutical companies, contract research organizations (CROs), and emerging biotechs to drive their research across the R&D value chain. It serves as an enterprise-wide system of record for pathology data and sits at the center of routine operations, enabling diverse workflows, streamlining collaboration, and unlocking new insights with artificial intelligence (AI). In doing so, the platform is enabling life sciences organizations to better tap into their pathology data from discovery to development to advance the next wave of innovation.

To see a live demonstration of the expanded Concentriq for Research, visit Proscia at booth #636 during the Society of Toxicology 62nd Annual Meeting and ToxExpo. Proscia will also be showcasing the new features during a live webinar on Wednesday, May 3 at 11 AM EDT.

About Proscia

Proscia is a software company that is accelerating pathology’s digital transformation to change the way we understand diseases like cancer. Its Concentriq digital pathology platform and powerful AI applications are advancing the 150-year-old standard of research and diagnosis towards a data-driven discipline, unlocking new insights that accelerate discovery, improve patient outcomes, and fulfill the promise of precision care. Leading diagnostic laboratories and 14 of the top 20 pharmaceutical companies rely on Proscia’s software each day. For more information, visit proscia.com.

[1] Wilson, E., Willoughby, R., & Wallach, M. (2016). CRO Industry Primer. Equity Research: Life Science Tools and Diagnostics. Credit Suisse. Retrieved from https://bit.ly/3FzTBWN

Share article on social media or email:

Ideal Option Opens 2nd Addiction Medicine Clinic in Deschutes County


Ideal Option, a national leader in evidence-based treatment for addiction to fentanyl, heroin, methamphetamine, alcohol and polysubstance, has been awarded grant funding through Oregon’s M110 initiative to expand services to Redmond. Patients will receive primarily buprenorphine-based medication-assisted treatment from an onsite addiction medicine specialist.

According to Deschutes County District Attorney John Hummel, fentanyl, a dangerous and highly addictive synthetic opioid, is largely to blame for overdose deaths skyrocketing in Central Oregon. Figures released by the Oregon Health Authority showed at least 29 people in Deschutes, Crook and Jefferson counties died from drug overdoses in 2021. At least 24 of the region’s drug overdose deaths occurred in Deschutes County, an 85% increase compared to 2019.

Ideal Option’s 2022 Annual Patient Outcomes Report for Oregon shows fentanyl positive rates at enrollment continue to rise and more patients are testing positive for multiple substances. In 2022, 62% of patients tested positive for more than one substance at enrollment and 30% tested positive for 3 or more substances. Among patients who remained in treatment with Ideal Option during 2022, urine drug testing shows:

  • 97% less fentanyl use
  • 88% less methamphetamine use
  • 85% less total opioid use
  • 96% less heroin use
  • 62% less benzodiazepine use

The new clinic in Redmond is Ideal Option’s second location in Deschutes County and is opening at a time of desperate need for expanded access to evidence-based treatment from experienced providers. Ideal Option has been specializing in addiction medicine using buprenorphine-based medications such as Suboxone® for 11 years and currently operates 87 clinics in 11 states.

“I am excited that our much-needed services are now available in Redmond,” said Shawnda Jennings, peer outreach specialist at Ideal Option. “As someone in recovery myself, I know how important it is to have easy access to treatment and am so grateful to be able to give back to the community that helped me.”

The new Ideal Option clinic in Redmond is open Monday – Thursday, 7:30 a.m. – 6 p.m. and is located at 1228 NW Canal Blvd, Redmond, OR 97756.

Most forms of insurance are accepted, including Medicare and Medicaid, and patients can typically get started on treatment for fentanyl, heroin, alcohol or other substances within 1-3 business days.

Patients can make an appointment by calling 1.877.522.1275 or visiting http://www.idealoption.com.

About Ideal Option

Headquartered in Kennewick, Washington, Ideal Option was founded in 2012 and has since helped more than 65,000 patients through a network of 87 office-based medication-assisted treatment (MAT) clinics across 11 states. With a mission to serve under-served communities, Ideal Option accepts most forms of insurance including Medicaid and Medicare. Financial assistance and payment plans are also available.

Ideal Option’s team of medical providers carry certifications in Addiction and Emergency Medicine, Internal, and Family Medicine, among other specialties. The company also employs social workers, caseworkers, counselors, and mental health practitioners. This holistic approach helps drive positive outcomes, including family stability, stable housing, improved overall health, and reduced rates of recidivism.

In all the communities it serves, Ideal Option collaborates with existing stakeholders and providers to improve the continuum of care. This approach includes partnerships with emergency rooms and county jail systems, where individuals with substance use disorder often appear, as well as collaborating with numerous support agencies and municipal programs addressing social needs such as housing, mental health, and nutrition support.

Share article on social media or email:

Ingenovis Health’s Newest Clinician Webinar to Focus on ‘Wellness from Within’


Ingenovis Health’s (Ingenovis) ACT Webinar Series for Healthcare Professionals, will host the second episode in its three-part self-care mini-series on March 23. The free monthly webinar series was launched in January as part of Ingenovis’ ACT (Advocacy. Career. Tools.) program.

What: Part two of the ‘Emerging a More Excellent You’ webinar mini-series, Self-Care 102: Wellness from Within, will focus on finding your center, the importance of mobility and physical health conditioning.

When: Thursday, March 23 at 2:30 p.m. EST

Participants: Webinar host – Dr. Robin Geiger, Ingenovis Senior Vice President of Clinician Advocacy

Guest speaker – Dr. Samantha Hedgspeth

Where: Attendees can register for the free Zoom event here.

Why: The ACT program serves as an integral part of Ingenovis’ overall purpose to build a home for healthcare talent across its seven category-leading brands. Created from insights collected from frontline workers, it serves to offer the essential tools and inspirational resources healthcare providers need to grow, flourish and advance in their careers, to help stem the tide of provider attrition.

The information in this webinar series is general, subject to change, should not be construed as professional advice from any of the hosts, presenters or sponsors, and is provided for informational purposes only.

Share article on social media or email:

Former Athens Vein & Thoracic Specialists to Change its Name to Athens Vein & Aesthetics


“This name change represents the evolution of the practice,” said Dr. Chris Malone. “We are a provider with experience performing a wide-range of procedures for health and wellness care, and we are excited to bring more focus to our expanded services.”

To better reflect the work they do as a provider for patients in vascular health and aesthetic wellness services, Athens Vein & Thoracic Specialists is changing its name to Athens Vein & Aesthetics.

Board certified thoracic surgeon, Dr. Chris Malone, has provided lifesaving vascular and thoracic care along with minimally invasive vein care to the community for nearly two decades. The practice has now expanded into offering a full suite of aesthetic services, including professional skin care products.

“This name change represents the evolution of the practice,” said Dr. Chris Malone. “We are a provider with experience performing a wide-range of procedures for health and wellness care, and we are excited to bring more focus to our expanded services.”

These changes embody the practice’s ethos that “healthy is the new beautiful.” Minimally invasive vascular and aesthetic treatments help patients feel good and look good.

In addition to office based vascular treatment and aesthetic services, Dr. Malone will continue to perform lifesaving, robotic assisted thoracic surgery at St. Mary’s Health Care System.

To learn more about the treatment of vein disease and the aesthetic options offered by the practice, visit their new website at AthensVeins.com.

Share article on social media or email: